Close Menu

Ovarian Cancer

News and reporting on ovarian cancer.

The targeted sequencing assay analyzes 12 genes and can be paired with the firm's BRCA gene testing kit.

An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.

In a proof-of-concept study, the group has demonstrated its platform could detect a biomarker of breast tumor metastasis and other disease biomarkers.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The agency reviewed data showing that HRD-positive patients on the olaparib/bevacizumab combination had median progression-free survival of 37.2 months.

The drugmaker will promote Zejula without a biomarker as a first-line maintenance option, and Myriad will highlight that patients with HRD are most likely to benefit.

The diagnostic will be covered when patients are tested according to the Japanese Organization of Hereditary Breast and Ovarian Cancer's criteria.

Australian researchers said that in a preliminary study they saw sensitivity improvements by adding IL-6 to other clinical measurements.

The company filed the application based on the PAOLA-1 data, which showed HRD-positive ovarian cancer patients saw pronounced benefit from the combo.

OvaCis is a CE-IVD marked in vitro diagnostic that can be used to assess epithelial ovarian cysts.

Pages